- $19.71bn
- $22.84bn
- $4.96bn
- 91
- 26
- 61
- 61
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 21.1 | ||
| PEG Ratio (f) | 2.43 | ||
| EPS Growth (f) | 9.52% | ||
| Dividend Yield (f) | 1.12% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.07 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 33.19 | ||
| Price to Sales | 3.65 | ||
| EV to EBITDA | 16.44 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.76% | ||
| Return on Equity | 9.1% | ||
| Operating Margin | 15.1% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2,782.17 | 3,030.89 | 3,107.52 | 4,585.06 | 4,957.84 | 5,459.31 | 5,780.55 | 13.61% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +32.19 | +8.2 | +5 | -8.61 | -2.63 | +87.23 | +9.52 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
STERIS plc is a provider of products and services that support patient care with an emphasis on infection prevention. The Company’s segments include Healthcare, Applied Sterilization Technologies, Life Sciences and Dental. The Healthcare segment is focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. Its Applied Sterilization Technologies (AST) segment is a third-party service provider for contract sterilization, as well as testing services needed to validate sterility services for medical device and pharmaceutical manufacturers. Its Life Sciences segment provides a comprehensive offering of products and services that support pharmaceutical manufacturing, primarily for vaccine and other biopharma customers focused on aseptic manufacturing. Its Dental segment provides a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems.
Directors
- Mohsen Sohi CHM (62)
- Daniel Carestio PRE (48)
- Michael Tokich CFO (52)
- John Zangerle SVP (54)
- Renato Tamaro VPR (52)
- Cary Majors VPR (46)
- Richard Breeden IND (71)
- Cynthia Feldmann IND (68)
- Christopher Holland IND (55)
- Jacqueline Kosecoff IND
- Paul Martin IND (63)
- Nirav Shah IND (48)
- Richard Steeves IND (59)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 22nd, 2016
- Public Since
- November 3rd, 2015
- No. of Shareholders
- 403
- No. of Employees
- 17,000
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 98,814,035
- Address
- Block a Riverside IV, DUBLIN, 2
- Web
- https://www.steris.com/
- Phone
- +353 12322000
- Contact
- Julie Winter
- Auditors
- Ernst & Young LLP
Latest News for STE
Upcoming Events for STE
Q4 2024 STERIS plc Earnings Release
Steris plc Annual Shareholders Meeting
Q1 2025 STERIS plc Earnings Release
Similar to STE
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Agiliti
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
FAQ
As of Today at 19:20 UTC, shares in Steris are trading at $199.51. This share price information is delayed by 15 minutes.
Shares in Steris last closed at $199.51 and the price had moved by +7.59% over the past 365 days. In terms of relative price strength the Steris share price has underperformed the S&P500 Index by -10.47% over the past year.
The overall consensus recommendation for Steris is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Steris dividend yield is 0.99% based on the trailing twelve month period.
Last year, Steris paid a total dividend of $1.98, and it currently has a trailing dividend yield of 0.99%. We do not have any data on when Steris is to next pay dividends.
We do not have data on when Steris is to next pay dividends. The historic dividend yield on Steris shares is currently 0.99%.
To buy shares in Steris you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $199.51, shares in Steris had a market capitalisation of $19.71bn.
Here are the trading details for Steris:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: STE
Based on an overall assessment of its quality, value and momentum Steris is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Steris is $239.86. That is 20.22% above the last closing price of $199.51.
Analysts covering Steris currently have a consensus Earnings Per Share (EPS) forecast of $8.63 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Steris. Over the past six months, its share price has underperformed the S&P500 Index by -21.96%.
As of the last closing price of $199.51, shares in Steris were trading -9.37% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Steris PE ratio based on its reported earnings over the past 12 months is 21.1. The shares last closed at $199.51.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Steris' management team is headed by:
- Mohsen Sohi - CHM
- Daniel Carestio - PRE
- Michael Tokich - CFO
- John Zangerle - SVP
- Renato Tamaro - VPR
- Cary Majors - VPR
- Richard Breeden - IND
- Cynthia Feldmann - IND
- Christopher Holland - IND
- Jacqueline Kosecoff - IND
- Paul Martin - IND
- Nirav Shah - IND
- Richard Steeves - IND